Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 124, Issue 3, 2017, Pages 474-484

  Pedersen, K ^a   Sorbye S W ^b   Kristiansen, I S ^a   Burger, E A ^a,c  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Biological markers; cervical intraepithelial neoplasia; cervical neoplasms; cost effectiveness; mass screening

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CERVICAL LESION; COLPOSCOPY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EMERGENCY HEALTH SERVICE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; NORWAY; PRACTICE GUIDELINE; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DISEASE; YOUNG ADULT; EARLY CANCER DIAGNOSIS; ECONOMICS; HUMAN PAPILLOMAVIRUS DNA TEST; PATHOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; UTERINE CERVIX; VAGINA SMEAR;

ADULT; BIOMARKERS; CERVIX UTERI; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; NORWAY; TRIAGE; UTERINE CERVICAL DISEASES; VAGINAL SMEARS; YOUNG ADULT;

EID: 84973463405     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.14135     Document Type: Article

References (39)

1. NHS Cervical Screening Programme. HPV Primary Screening Pilot Announced. 2012 [www.cancerscreening.nhs.uk/cervical/nes/021.html]. Accessed 16 June 2015.
2. Vink MA, Bogaards JA, Meijer CJ, Berkhof J. Primary human papillomavirus DNA screening for cervical cancer prevention: can the screening interval be safely extended? Int J Cancer 2015;137:420–7.
3. zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology 2009;384:260–5.
4. Bosch FX, de Sanjose S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007;23:213–27.
5. Nygard M, Roysland K, Campbell S, Dillner J. Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme. BMJ Open 2014;4:e003460.
6. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007;197:356.e1–6.
7. Sharp L, Cotton S, Cochran C, Gray N, Little J, Neal K, et al. After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. BJOG 2009;116:1506–14.
8. WHO Guidelines Approved by the Guidelines Review Committee. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. Geneva: World Health Organization Copyright (c) World Health Organization; 2013.
9. Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers 2007;23:315–30.
10. Pedersen K, Sorbye SW, Burger EA, Lonnberg S, Kristiansen IS. Using decision-analytic modeling to isolate interventions that are efficient, feasible and optimal: an application from the Norwegian Cervical Cancer Screening Program. Value Health 2015;18:1088–97.
11. Nygard M, Andreassen T, Berland J, Hagen B, Hagmar B, Iversen O-E, et al. HPV-testing in primary cervical cancer screening. Oslo: The Norwegian Directorate of Health; 2013.
12. The Medical Birth Registry of Norway, 2014.
13. Jin G, LanLan Z, Li C, Dan Z. Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis. Arch Gynecol Obstet 2014;289:85–99.
14. Cancer Registry of Norway. The Norwegian Cervical Cancer Screening Program 2013: Oslo, Norway, 2013.
15. Norwegian Medical Association. Normal tariff for private general practice 2014–15. [http://normaltariffen.legeforeningen.no/pdf/Fastlegetariff_2014.pdf] Accessed: 22 April 2015.
16. Norwegian Medical Association. Normal tariff for private specialist practice 2014-15. [http://normaltariffen.legeforeningen.no/pdf/Normaltariff_2014.pdf] Accessed: 22 April 2015.
17. Verdoodt F, Szarewski A, Halfon P, Cuschieri K, Arbyn M. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Cancer Cytopathol 2013;121:675–87.
18. Zappacosta R, Gatta DM, Marinucci P, Capanna S, Lattanzio G, Caraceni D, et al. Role of E6/E7 mRNA test in the diagnostic algorithm of HPV-positive patients showing ASCUS and LSIL: clinical and economic implications in a publicly financed healthcare system. Expert Rev Mol Diagn 2015;15:137–50.
19. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013;17 (Suppl. 1):S1–s27.
20. Skare GB, Lönnberg S. The Norwegian Cervical Cancer Screening Program. Annual report 2012, 2013. Oslo: Cancer Registry of Norway.
21. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94–101.
22. Castle PE, Fetterman B, Thomas Cox J, Shaber R, Poitras N, Lorey T, et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol 2010;116:76–84.
23. Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13:1–150, iii–iv.
24. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006;7:547–55.
25. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011;135:468–75.
26. Stoler MH, Wright TC Jr, Cuzick J, Dockter J, Reid JL, Getman D, et al. APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. Am J Obstet Gynecol 2013;208:144:e1–8.
27. Kisser A, Zechmeister-Koss I. A systematic review of p16/Ki-67 immuno-testing for triage of low grade cervical cytology. BJOG 2015;122:64–70.
28. Arbyn M, Roelens J, Simoens C, Buntinx F, Paraskevaidis E, Martin-Hirsch PP, et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev 2013;3:Cd008054.
29. Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, et al. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer 2013;132:101–8.
30. Dalla Palma P, Giorgi Rossi P, Collina G, Buccoliero AM, Ghiringhello B, Lestani M, et al. The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial. Am J Clin Pathol 2008;129:75–80.
31. Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, Paavonen J, et al. The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer 2011;128:1354–62.
32. Zuchna C, Hager M, Tringler B, Georgoulopoulos A, Ciresa-Koenig A, Volgger B, et al. Diagnostic accuracy of guided cervical biopsies: a prospective multicenter study comparing the histopathology of simultaneous biopsy and cone specimen. Am J Obstet Gynecol 2010;203:321.e1–6.
33. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009;113:18–25.
34. Pedersen K, Lonnberg S, Skare GB, Sorbye SW, Burger EA, Kristiansen IS. [Costs of the Norwegian Cervical Cancer Screening Program]. Sykepleien Forskning 2015;10:62–71.
35. Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer 2012;106:1571–8.
36. The Central Bank of Norway. Average exchange rates 2014, 2014. [www.norgesbank.no/Statistikk/Valutakurser/valuta/EUR/] Accessed: 19 January 2016].
37. Ting J, Smith JS, Myers ER. Cost-Effectiveness of High-Risk Human Papillomavirus Testing With Messenger RNA Versus DNA Under United States Guidelines for Cervical Cancer Screening. J Low Genit Tract Dis 2015;10:e0136708.
38. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008;17:2536–45.
39. Burger EA, Kornor H, Klemp M, Lauvrak V, Kristiansen IS. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol 2011;120:430–8.